cetuximab,pembrolizumab,encorafenib,adagrasib,afatinib
mirati,eli lilly,merck,pfizer,boehringer ingelheim
['encorafenib', 'cetuximab', 'krystal-1', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
krystal-1 update : kras g12c druggable at last, more effectively with egfri cetuximab addition in mcrc (as with brafi encorafenib in braf v600e mutated mcrc). 2nd-line randomized krystal-10 ongoing! 
GI oncologist, MD, PhD (FRA)